You are here
TGA grants provisional determination to Pfizer Australia's COVID-19 treatment PF-07321332 + ritonavir
On 1 October 2021, the TGA granted provisional determination to Pfizer Australia in relation to a new combination medicine containing PF-07321332 and ritonavir, for the treatment of adult patients with symptomatic, confirmed coronavirus infection.
PF-07321332 is an oral antiviral treatment. It is intended to be administered in combination with low-dose ritonavir - to maintain plasma levels of PF-07321332 for the duration of the treatment.
The granting of a provisional determination means that the TGA has made a decision that Pfizer Australia is now eligible to apply for provisional registration of this treatment in the Australian Register of Therapeutic Goods (ARTG). Provisional determination is the first step in the process. It is anticipated that Pfizer will submit an application for provisional registration shortly.
Further information on all COVID-19 vaccines and treatments can be found on the TGA's website.
Contact for members of the media:
- Email: firstname.lastname@example.org
- Phone: 02 6289 7400